Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -4.35% | -14.40% | -30.82% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
Sales 2024 * | 832K 69.59M | Sales 2025 * | 8.66M 724M | Capitalization | 17.86M 1.49B |
---|---|---|---|---|---|
Net income 2024 * | -41M -3.43B | Net income 2025 * | -40M -3.34B | EV / Sales 2024 * | 21.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.06 x |
P/E ratio 2024 * |
-0.65
x | P/E ratio 2025 * |
-1.2
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.97% |
Latest transcript on Lumos Pharma, Inc.
1 day | -4.35% | ||
1 week | -14.40% | ||
Current month | -2.22% | ||
1 month | -13.39% | ||
3 months | -19.41% | ||
6 months | -27.87% | ||
Current year | -30.82% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 01/10/01 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 01/20/01 |
John McKew
PSD | President | 59 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 01/12/01 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 01/10/01 |
Kevin Lalande
BRD | Director/Board Member | 51 | 01/14/01 |
Date | Price | Change | Volume |
---|---|---|---|
18/24/18 | 2.2 | -4.35% | 13,334 |
17/24/17 | 2.3 | -3.77% | 3,336 |
14/24/14 | 2.39 | -4.02% | 13,172 |
13/24/13 | 2.49 | -3.11% | 1,909 |
12/24/12 | 2.57 | +0.78% | 8,671 |
Delayed Quote Nasdaq, June 19, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.82% | 17.86M | |
+34.01% | 51.07B | |
+34.69% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- LUMO Stock